Innovative Collaboration Targets HER3 in Cancer Diagnostics
Collaboration to Enhance Cancer Treatment
The Department of Clinical and Molecular Medicine of Sapienza University of Rome (DMCM), along with Takis S.r.l. and Tethis S.p.A., has embarked on a significant joint initiative aimed at revolutionizing treatments for lung cancer. The primary focus of this collaboration is to expedite research on HER3-targeted therapies and develop innovative companion diagnostics that can help identify the best candidates for treatment.
Advancements in HER3-Targeted Therapies
As part of the HERCART project, which receives funding from the Italian Ministry of Enterprises and Made in Italy, Takis and DMCM are dedicated to creating novel antibody-based therapies. One major component of this effort includes developing a bispecific T-cell engager known as Rever3mAb, specifically designed to attach to the HER3 receptor, which is commonly overexpressed in certain cancers.
Innovative Diagnostic Techniques
To complement these advancements, DMCM will collaborate with Tethis to implement cutting-edge liquid biopsy analyses using Tethis’ state-of-the-art See.d instrument. This instrument will be instrumental in efficiently detecting HER3-positive circulating tumor cells (CTCs) from lung cancer patients. The process involves collecting blood samples which will then be processed at DMCM, showcasing a highly coordinated effort to integrate innovative treatment with reliable diagnostics.
From Concept to Clinical Practice
Following successful trials with model cells, the partnership is set to enter a clinical phase. Blood samples from patients will be collected at Sant'Andrea Hospital in Rome, with subsequent analysis performed at DMCM. The prepared cytology slides will be analyzed for the presence of HER3-positive CTCs using Takis' HER3-specific antibody, marking a pivotal moment in the journey towards personalized medicine.
Expert Insights on the Collaboration
Giuseppe Roscilli, CTO of Takis, emphasized the importance of pairing new therapeutic developments with appropriate diagnostics, stating, "Innovation in cancer therapeutics and diagnostics must go hand in hand—new therapies require relevant diagnostics for patient selection." Moreover, Holger Neecke, CEO of Tethis, pointed out the impartiality of the See.d instrument in preparing cytology slides, which helps in obtaining a more comprehensive representation of CTCs. This enhances the potential of developing accurate companion diagnostics aimed at specific protein biomarkers.
Paving the Way for Future Therapies
Claudia De Vitis, a researcher at DMCM, noted that understanding HER3-positive cells in blood samples could catalyze the development of innovative therapeutic solutions aimed specifically at HER3. The collaboration signifies a merging of academic research, clinical practice, and diagnostics that can lead to tailored solutions in oncology.
The Significance of Personalized Medicine
Rita Mancini, a full professor at DMCM, stated, "This collaboration between an academic center, a hospital, a biotech firm, and a diagnostics company illustrates how blending innovative research with technology can fast-track the emergence of targeted therapies and companion diagnostics for the benefit of patients." This forward-thinking partnership aims to ultimately improve patient outcomes through targeted and personalized treatment approaches, illustrating the essential role of collaboration in advancing cancer research.
About the Department of Clinical and Molecular Medicine
The Department of Clinical and Molecular Medicine at Sapienza University of Rome plays a crucial role in the field of translational research. Established in 2009, it seeks to unify various scientific disciplines related to molecular medicine, clinical medicine, and diagnostics, ultimately aiming to deliver high-quality medical care through integrated research efforts. Its affiliations with the Sant'Andrea Hospital further enhance its capability for impactful clinical studies.
About Takis
Takis is a biotech company, based in Rome, specializes in developing vaccines and therapeutic antibodies targeting both solid tumors and infectious diseases. Founded by seasoned scientists with deep roots in oncology research, Takis has amassed a wealth of experience and technology, including innovative DNA delivery systems, to enhance therapeutic solutions. The company remains dedicated to advancing treatments through a robust pipeline that includes humanized monoclonal antibodies and bispecifics.
About Tethis
Tethis is a pioneering company devoted to revolutionizing diagnostics, particularly through the integration of liquid biopsy into clinical settings. By standardizing blood sample preparations, Tethis ensures that liquid biopsy specimens maintain the highest quality, enabling comprehensive analysis of crucial biomarkers. Their unique SmartBioSurface slides, combined with the See.d instrument, heighten the sensitivity of identifying circulating tumor cells, thereby enhancing cancer diagnostic capabilities.
Frequently Asked Questions
What is the main goal of the collaboration between DMCM, Takis, and Tethis?
The collaboration aims to accelerate research on HER3-targeted therapies and develop companion diagnostics for lung cancer patients.
What innovative therapies are being developed?
Innovative antibody-based therapies, including a bispecific T-cell engager targeting the HER3 receptor, are being developed under this collaboration.
How is the collaboration bridging research and clinical practice?
By integrating advanced diagnostic methods with therapeutic development, the partnership enhances personalized medicine through improved patient selection for treatment.
What role does the See.d instrument play in this initiative?
The See.d instrument aids in the liquid biopsy analysis, facilitating the detection of HER3-positive circulating tumor cells from blood samples.
How does this initiative benefit lung cancer patients?
This collaboration aims to identify patients most likely to benefit from HER3-targeted treatments, ultimately improving outcomes through personalized approaches.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.